InvestorsHub Logo
Followers 8
Posts 1323
Boards Moderated 0
Alias Born 10/11/2013

Re: Deborah1 post# 32

Tuesday, 04/21/2015 10:54:33 PM

Tuesday, April 21, 2015 10:54:33 PM

Post# of 138
Gern sold their entire stem cell IP portfolio to Biotime (BTX), including two major product candidates in clinical trials - one is a cancer vaccine and the other remylinates nerve tissues. Biotime spun off Asterias as a subsidiary to continue the development of these two products both of which have mind blowing potential - if the next phases of the clinical trials continue to show positive results. BTX & GERN, to a much lesser degree, holds a substantial portion of AST shares. Many of the key people in BTX are former GERN leadership personell.
This press release came out today which, I believe, is why the stock is soaring.